NEPA (Netupitant/Palonosetron) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients Receiving Highly or Moderately Emetogenic Chemotherapy Who Experienced Breakthrough CINV in Cycle 1 of Chemotherapy: A Phase II Clinical Trial.

NEPA (Netupitant/Palonosetron) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients Receiving Highly or Moderately Emetogenic Chemotherapy Who Experienced Breakthrough CINV in Cycle 1 of Chemotherapy: A Phase II Clinical Trial. Cancer Med. 2025 Apr; 14(7):e70549.

View in: PubMed

subject areas

Adult
Aged
Antiemetics
Antineoplastic Agents
Antineoplastic Combined Chemotherapy Protocols
Benzeneacetamides
Dexamethasone
Drug Combinations
Female
Humans
Isoquinolines
Male
Middle Aged
Nausea
Neoplasms
Piperazines
Pyridines
Treatment Outcome
Vomiting

authors with profiles

Rudolph Navari